The Department of Health and Human Services yesterday took action to provide a pathway for all states and territories to increase access to critical COVID-19 monoclonal antibody therapeutics. HHS executed an amendment to the Public Readiness and Emergency Preparedness Act Declaration that expands the pool of professionals now covered under the PREP Act for the administration of COVID-19 monoclonal antibody therapeutics. Specifically, the amendment includes coverage of licensed pharmacists, pharmacy technicians, and pharmacy interns when administering COVID-19 monoclonal antibody therapeutics orally, through intramuscular injection, or through subcutaneous injection. The provision was included as part of President Biden’s COVID-19 action plan released yesterday. For details on other provisions included in the action plan and AHA’s reaction, see yesterday’s Special Bulletin.

Related News Articles

Headline
Health care providers who received approval to submit a late report on how they used Provider Relief Fund payments received from July 1 to Dec. 31, 2020, must…
Headline
Hospitals are contending with an exhausted workforce, backlogs of care deferred by the pandemic, cracks in the supply chain and a tsunami of financial…
Headline
In a study examining electronic health records for adults who visited an inpatient or outpatient facility between March 2020 and November 2021, COVID-19…
Headline
The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19…
Headline
Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial involving 1,678 children who received the…
Headline
The Centers for Disease Control and Prevention yesterday recommended children age 5-11 receive a booster dose five months after completing the Pfizer COVID-19…